Allan J. Pantuck

28.3k total citations · 6 hit papers
350 papers, 16.4k citations indexed

About

Allan J. Pantuck is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Allan J. Pantuck has authored 350 papers receiving a total of 16.4k indexed citations (citations by other indexed papers that have themselves been cited), including 252 papers in Pulmonary and Respiratory Medicine, 174 papers in Molecular Biology and 105 papers in Surgery. Recurrent topics in Allan J. Pantuck's work include Renal cell carcinoma treatment (210 papers), Renal and related cancers (125 papers) and Bladder and Urothelial Cancer Treatments (89 papers). Allan J. Pantuck is often cited by papers focused on Renal cell carcinoma treatment (210 papers), Renal and related cancers (125 papers) and Bladder and Urothelial Cancer Treatments (89 papers). Allan J. Pantuck collaborates with scholars based in United States, France and Germany. Allan J. Pantuck's co-authors include Arie S. Belldegrun, Amnon Zisman, Robert A. Figlin, Jonathan Said, Tobias Klatte, Brian Shuch, David B. Seligson, Oleg Shvarts, Fairooz F. Kabbinavar and Debby H. Chao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Allan J. Pantuck

344 papers receiving 16.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA

2001 643 citations Allan J. Pantuck, Arie S. Belldegrun et al. The Journal of Urology profile →
Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer

1992 584 citations Allan J. Pantuck et al. The Journal of Urology profile →
Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System

2001 542 citations Allan J. Pantuck, Jonathan Said et al. Journal of Clinical Oncology profile →
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

2005 535 citations Robert A. Figlin, Arie S. Belldegrun et al. Journal of Clinical Oncology profile →
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.

2003 514 citations David B. Seligson, Allan J. Pantuck et al. profile →
Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma

2002 501 citations Allan J. Pantuck, Jonathan Said et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Allan J. Pantuck United States	70	11.4k	8.9k	4.1k	3.6k	3.2k	350	16.4k
George Wilding United States	72	12.1k 1.1×	9.9k 1.1×	5.3k 1.3×	2.0k 0.6×	6.8k 2.2×	308	22.3k
Arie S. Belldegrun United States	85	16.1k 1.4×	13.0k 1.5×	5.7k 1.4×	5.2k 1.4×	5.6k 1.8×	454	24.2k
E. David Crawford United States	64	11.4k 1.0×	4.0k 0.5×	3.2k 0.8×	4.4k 1.2×	4.0k 1.3×	284	17.5k
Camillo Porta Italy	57	12.2k 1.1×	10.0k 1.1×	5.8k 1.4×	2.3k 0.6×	7.0k 2.2×	576	21.1k
M. Scott Lucia United States	54	7.7k 0.7×	3.2k 0.4×	1.8k 0.4×	2.2k 0.6×	2.2k 0.7×	193	14.4k
Yuichi Ishikawa Japan	53	9.7k 0.9×	7.5k 0.9×	3.8k 0.9×	1.4k 0.4×	8.8k 2.8×	265	17.9k
David J. Grignon United States	76	14.6k 1.3×	6.0k 0.7×	3.7k 0.9×	4.9k 1.4×	3.5k 1.1×	364	20.8k
Jiafu Ji China	53	5.3k 0.5×	5.5k 0.6×	2.5k 0.6×	3.0k 0.8×	4.3k 1.4×	486	14.4k
Dafydd G. Thomas United States	62	3.2k 0.3×	6.0k 0.7×	3.0k 0.7×	1.6k 0.4×	3.9k 1.2×	221	13.4k
Stefano Cascinu Italy	63	7.3k 0.6×	4.2k 0.5×	3.4k 0.8×	3.4k 0.9×	11.2k 3.5×	648	18.3k

Countries citing papers authored by Allan J. Pantuck

Since Specialization

Citations

This map shows the geographic impact of Allan J. Pantuck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan J. Pantuck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan J. Pantuck more than expected).

Fields of papers citing papers by Allan J. Pantuck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan J. Pantuck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan J. Pantuck. The network helps show where Allan J. Pantuck may publish in the future.

Co-authorship network of co-authors of Allan J. Pantuck

This figure shows the co-authorship network connecting the top 25 collaborators of Allan J. Pantuck. A scholar is included among the top collaborators of Allan J. Pantuck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan J. Pantuck. Allan J. Pantuck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abel, Melissa L., et al.. (2023). The Potential Revolution of Cancer Treatment with CRISPR Technology. Cancers. 15(6). 1813–1813. 36 indexed citations

Sarker, Debashis, Nancy A. Dawson, Ana M. Aparicio, et al.. (2021). A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 27(19). 5248–5257. 22 indexed citations

Drakaki, Alexandra, Allan J. Pantuck, Shivani K. Mhatre, et al.. (2020). “Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 39(1). 76.e15–76.e22. 10 indexed citations

Aggarwal, Rahul, Michael T. Schweizer, David M. Nanus, et al.. (2020). A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 26(20). 5338–5347. 97 indexed citations

Lenis, Andrew T., Vishnukamal Golla, Aydin Pooli, et al.. (2019). Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus—Trends and effect on overall survival. Urologic Oncology Seminars and Original Investigations. 37(9). 577.e9–577.e16. 14 indexed citations

Κουτσιούμπα, Μαρίνα, Hsiao‐Wang Chen, Neil A. O’Brien, et al.. (2018). MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer. Molecular Cancer Therapeutics. 17(7). 1430–1440. 19 indexed citations

George, Daniel J., Jean-François Martini, Michael Staehler, et al.. (2018). Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical Cancer Research. 25(4). 1165–1173. 18 indexed citations

Salmasi, Amirali, Izak Faiena, Andrew T. Lenis, et al.. (2018). Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 36(12). 527.e13–527.e19. 17 indexed citations

Young, Jonathan R., et al.. (2017). Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma. Academic Radiology. 24(10). 1226–1232. 18 indexed citations

10.

Kroeger, Nils, David B. Seligson, Sabina Signoretti, et al.. (2014). Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α. European Journal of Cancer. 50(8). 1531–1540. 25 indexed citations

11.

Young, Jonathan R., Daniel Margolis, Steven Sauk, et al.. (2014). Clear cell renal cell carcinoma: multiphasic MDCT enhancement can predict the loss of chromosome 8p. Abdominal Imaging. 39(3). 543–549. 8 indexed citations

12.

Belldegrun, Arie S., Karim Chamie, Paul Bevan, et al.. (2013). ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—Results and implications for adjuvant clinical trials.. Journal of Clinical Oncology. 31(15_suppl). 4507–4507. 37 indexed citations

13.

Pantuck, Allan J., Jiabin An, Huiren Liu, & Matthew B. Rettig. (2010). NF-κB–Dependent Plasticity of the Epithelial to Mesenchymal Transition Induced by Von Hippel-Lindau Inactivation in Renal Cell Carcinomas. Cancer Research. 70(2). 752–761. 77 indexed citations

14.

Klatte, Tobias, Priya Rao, Michela de Martino, et al.. (2009). Cytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 27(5). 746–753. 151 indexed citations

15.

Klatte, Tobias & Allan J. Pantuck. (2008). Molecular Biology of Renal Cortical Tumors. Urologic Clinics of North America. 35(4). 573–580. 25 indexed citations

16.

Shuch, Brian, Tobias Klatte, Stephen B. Riggs, et al.. (2008). Performance status and cytoreductive nephrectomy. Cancer. 113(6). 1324–1331. 45 indexed citations

17.

Klatte, Tobias, Arie S. Belldegrun, & Allan J. Pantuck. (2008). The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. British Journal of Urology. 101(s4). 45–48. 15 indexed citations

18.

Sartippour, Maryam, Navindra P. Seeram, Jian Yu Rao, et al.. (2008). Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. International Journal of Oncology. 32(2). 475–80. 94 indexed citations

19.

Mestas, Javier, Marie D. Burdick, Karen L. Reckamp, et al.. (2005). The Role of CXCR2/CXCR2 Ligand Biological Axis in Renal Cell Carcinoma. The Journal of Immunology. 175(8). 5351–5357. 118 indexed citations

20.

Murphy, David, Allan J. Pantuck, Kiron M. Das, et al.. (1999). FEMALE URETHRAL ADENOCARCINOMA: IMMUNOHISTOCHEMICAL EVIDENCE OF MORE THAN 1 TISSUE OF ORIGIN. The Journal of Urology. 161(6). 1881–1884. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact